Baxter Biopharma Solutions Sterile Manufacturing Agreement for Novavax Covid-19 Vaccine Announced
Baxter International has announced that Baxter BioPharma Solutions has entered into an agreement to provide...
The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting from annual strain selection.
The timeline for development of a seasonal influenza vaccine starts with a meeting by an FDA advisory committee in March to decide which strains to include in the next season’s vaccine which in turn must be produced, released, and distributed to pharmacies, clinics, and physician offices in as little as 6 months.
Baxter International has announced that Baxter BioPharma Solutions has entered into an agreement to provide...
Global leader in sterile medication production and delivery, Baxter International, is pleased to announce a...
Baxter International Inc representatives globally are rising to the call and making a difference in...
Cancer incidence is on the rise and cytotoxic therapies continue to be at the centre...